Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study comparing Iressa vs Tarceva in EGFR FISH+ advanced NSCLC
2006-001197-24Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Gefitinib arm with Erlotinib arm (2 arms). Primary endpoint: Progression-free survival. Started Jul 2006; status: completed.
02
Drugs
gefitiniberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-001197-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001197-24.